{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T16:17:42Z","timestamp":1758817062587},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone Reports"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.bonr.2024.101753","type":"journal-article","created":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T11:51:03Z","timestamp":1711108263000},"page":"101753","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Lessons learned from the real-world diagnosis and management of hereditary hypophosphatemic rickets"],"prefix":"10.1016","volume":"21","author":[{"given":"Deepti","family":"Chaturvedi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taif EmadEldin","family":"Mehasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Assia","family":"Benbrahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lubna","family":"ElDeeb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asma","family":"Deeb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bonr.2024.101753_bb0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193388","article-title":"Clinical and genetic characteristics of 15 families with hereditary hypophosphatemia: novel mutations in PHEX and SLC34A3","volume":"13","author":"Acar","year":"2018","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.bonr.2024.101753_bb0010","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1210\/clinem\/dgac488","article-title":"Approach to Hypophosphatemic rickets","volume":"108","author":"Ackah","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7","key":"10.1016\/j.bonr.2024.101753_bb0015","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/adc.2009.173195","article-title":"Recent trends and clinical features of childhood vitamin D deficiency presenting to a children\u2019s hospital in Glasgow","volume":"96","author":"Ahmed","year":"2011","journal-title":"Arch. Dis. Child."},{"issue":"1","key":"10.1016\/j.bonr.2024.101753_bb0020","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11657-021-00879-9","article-title":"Diagnosis and management of X-linked hypophosphatemia in children and adolescent in the Gulf cooperation council countries","volume":"16","author":"Al Juraibah","year":"2021","journal-title":"Arch. Osteoporos."},{"issue":"1","key":"10.1016\/j.bonr.2024.101753_bb0025","first-page":"61","article-title":"X-linked hypophosphatemic rickets (PHEX mutation): a case report and literature review","volume":"17","author":"Alenazi","year":"2017","journal-title":"Sudan J Paediatr."},{"issue":"12","key":"10.1016\/j.bonr.2024.101753_bb0030","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1515\/jpem-2021-0387","article-title":"Long-term effect of conventional phosphate and calcitriol treatment on metabolic recovery and catch-up growth in children with PHEX mutation","volume":"34","author":"Alikasifoglu","year":"2021","journal-title":"J. Pediatr. Endocrinol. Metab."},{"issue":"10","key":"10.1016\/j.bonr.2024.101753_bb0035","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1210\/clinem\/dgac433","article-title":"Burosumab treatment for autosomal recessive Hypophosphatemic rickets type 1 (ARHR1)","volume":"107","author":"Bai","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.bonr.2024.101753_bb0040","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1530\/EJE-08-0818","article-title":"Incidence and prevalence of nutritional and hereditary rickets in southern Denmark","volume":"160","author":"Beck-Nielsen","year":"2009","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.bonr.2024.101753_bb0045","doi-asserted-by":"crossref","first-page":"17101","DOI":"10.1038\/nrdp.2017.101","volume":"3","author":"Carpenter","year":"2017","journal-title":"Rickets. Nat Rev Dis Primers."},{"issue":"21","key":"10.1016\/j.bonr.2024.101753_bb0050","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","article-title":"Burosumab therapy in children with X-linked hypophosphatemia","volume":"378","author":"Carpenter","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bonr.2024.101753_bb0055","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bone.2017.01.034","article-title":"Heritable and acquired disorders of phosphate metabolism: etiologies involving FGF23 and current therapeutics","volume":"102","author":"Clinkenbeard","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.bonr.2024.101753_bb0060","series-title":"ACGS Best Practice Guidelines for Variant Classification in Rare","author":"Durkie","year":"2023"},{"issue":"1","key":"10.1016\/j.bonr.2024.101753_bb0065","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0169-6009(08)80127-4","article-title":"X-linked hypophosphatemic rickets: a disease often unknown to affected patients","volume":"24","author":"Econs","year":"1994","journal-title":"Bone Miner."},{"issue":"1","key":"10.1016\/j.bonr.2024.101753_bb0070","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13052-019-0654-6","article-title":"X-linked hypophosphatemic rickets: an Italian experts\u2019 opinion survey","volume":"45","author":"Emma","year":"2019","journal-title":"Ital. J. Pediatr."},{"issue":"9","key":"10.1016\/j.bonr.2024.101753_bb0075","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1507\/endocrj.EJ15-0275","article-title":"Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment","volume":"62","author":"Endo","year":"2015","journal-title":"Endocr. J."},{"issue":"3","key":"10.1016\/j.bonr.2024.101753_bb0080","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1681\/ASN.2017080840","article-title":"Acidosis and deafness in patients with recessive mutations in FOXI1","volume":"29","author":"Enerback","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"issue":"9917","key":"10.1016\/j.bonr.2024.101753_bb0085","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0140-6736(14)60211-7","article-title":"Hospitalisation for children with rickets in England: a historical perspective","volume":"383","author":"Goldacre","year":"2014","journal-title":"Lancet"},{"issue":"Suppl. 2","key":"10.1016\/j.bonr.2024.101753_bb0090","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s12325-019-01184-1","article-title":"Hypophosphataemic rickets: diagnosis algorithm-how not to make a mistake","volume":"37","author":"Gonzalez-Lamuno","year":"2020","journal-title":"Adv. Ther."},{"issue":"10189","key":"10.1016\/j.bonr.2024.101753_bb0095","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1016\/S0140-6736(19)31054-2","article-title":"Burosumab treatment of children with X-linked hypophosphataemic rickets","volume":"393","author":"Gordon","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.bonr.2024.101753_bb0100","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","article-title":"Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia","volume":"15","author":"Haffner","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"issue":"10189","key":"10.1016\/j.bonr.2024.101753_bb0105","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","article-title":"Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial","volume":"393","author":"Imel","year":"2019","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.bonr.2024.101753_bb0110","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/jbmr.3475","article-title":"A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of Burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis","volume":"33","author":"Insogna","year":"2018","journal-title":"J. Bone Miner. Res."},{"issue":"6","key":"10.1016\/j.bonr.2024.101753_bb0115","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1210\/jc.2013-4455","article-title":"Age-based reference ranges for annual height velocity in US children","volume":"99","author":"Kelly","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.bonr.2024.101753_bb0120","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1159\/000495393","article-title":"Phosphate homeostasis, inflammation and the regulation of FGF-23","volume":"43","author":"Lang","year":"2018","journal-title":"Kidney Blood Press. Res."},{"key":"10.1016\/j.bonr.2024.101753_bb0125","article-title":"Consensus recommendations for the diagnosis and management of X-linked hypophosphatemia in Belgium","volume":"12","author":"Laurent","year":"2021","journal-title":"Front Endocrinol (Lausanne)."},{"key":"10.1016\/j.bonr.2024.101753_bb0130","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3389\/fped.2020.00315","article-title":"Diagnosis and Management of Vitamin D Dependent Rickets","volume":"8","author":"Levine","year":"2020","journal-title":"Front. Pediatr."},{"issue":"8","key":"10.1016\/j.bonr.2024.101753_bb0135","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1210\/jc.2003-030036","article-title":"Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets","volume":"88","author":"Makitie","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.bonr.2024.101753_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmg.2022.104540","article-title":"Genetic and clinical profile of patients with hypophosphatemic rickets","volume":"65","author":"Marik","year":"2022","journal-title":"Eur. J. Med. Genet."},{"issue":"4","key":"10.1016\/j.bonr.2024.101753_bb0145","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00467-011-2046-z","article-title":"Growth in PHEX-associated X-linked hypophosphatemic rickets: the importance of early treatment","volume":"27","author":"Quinlan","year":"2012","journal-title":"Pediatr. Nephrol."},{"issue":"2","key":"10.1016\/j.bonr.2024.101753_bb0150","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1530\/EJE-15-0515","article-title":"Hereditary hypophosphatemia in Norway: a retrospective population-based study of genotypes, phenotypes, and treatment complications","volume":"174","author":"Rafaelsen","year":"2016","journal-title":"Eur. J. Endocrinol."},{"issue":"27","key":"10.1016\/j.bonr.2024.101753_bb0155","doi-asserted-by":"crossref","first-page":"9637","DOI":"10.1073\/pnas.0502249102","article-title":"Hypophosphatemia leads to rickets by impairing caspase-mediated apoptosis of hypertrophic chondrocytes","volume":"102","author":"Sabbagh","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bonr.2024.101753_bb0160","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3389\/fendo.2020.00338","article-title":"Clinical evidence for the benefits of Burosumab therapy for X-linked hypophosphatemia (XLH) and other conditions in adults and children","volume":"11","author":"Schindeler","year":"2020","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"Suppl. 2","key":"10.1016\/j.bonr.2024.101753_bb0165","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1186\/s13023-023-02883-3","article-title":"XLH matters 2022: insights and recommendations to improve outcomes for people living with X-linked hypophosphataemia (XLH)","volume":"18","author":"Seefried","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"issue":"Suppl","key":"10.1016\/j.bonr.2024.101753_bb0170","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.3177\/jnsv.61.S119","article-title":"The role of sodium-dependent phosphate transporter in phosphate homeostasis","volume":"61","author":"Segawa","year":"2015","journal-title":"J. Nutr. Sci. Vitaminol. (Tokyo)"},{"issue":"2","key":"10.1016\/j.bonr.2024.101753_bb0175","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s00247-012-2532-x","article-title":"Rickets: part I","volume":"43","author":"Shore","year":"2013","journal-title":"Pediatr. Radiol."},{"issue":"7","key":"10.1016\/j.bonr.2024.101753_bb0180","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1210\/js.2018-00365","article-title":"The lifelong impact of X-linked hypophosphatemia: results from a burden of disease survey","volume":"3","author":"Skrinar","year":"2019","journal-title":"J Endocr Soc."},{"issue":"9","key":"10.1016\/j.bonr.2024.101753_bb0185","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.2174\/1871530323666230227142202","article-title":"A new de novo mosaic mutation of PHEX gene: a case report of a boy with Hypophosphatemic rickets","volume":"23","author":"Terracciano","year":"2023","journal-title":"Endocr. Metab. Immune Disord. Drug Targets"},{"issue":"11","key":"10.1016\/j.bonr.2024.101753_bb0190","first-page":"4075","article-title":"X-linked hypophosphatemia: a search for gender, race, anticipation, or parent of origin effects on disease expression in children","volume":"81","author":"Whyte","year":"1996","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.bonr.2024.101753_bb0195","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S2213-8587(18)30338-3","article-title":"Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial","volume":"7","author":"Whyte","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"10.1016\/j.bonr.2024.101753_bb0200","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/s13023-022-02452-0","article-title":"Health-related quality of life of X-linked hypophosphatemia in Spain","volume":"17","author":"Yanes","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"issue":"9","key":"10.1016\/j.bonr.2024.101753_bb0205","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1002\/jbmr.4035","article-title":"Functional characterization of PHEX gene variants in children with X-linked Hypophosphatemic rickets shows no evidence of genotype-phenotype correlation","volume":"35","author":"Zheng","year":"2020","journal-title":"J. Bone Miner. Res."}],"container-title":["Bone Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352187224000202?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352187224000202?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T13:17:17Z","timestamp":1718543837000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352187224000202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":41,"alternative-id":["S2352187224000202"],"URL":"https:\/\/doi.org\/10.1016\/j.bonr.2024.101753","relation":{},"ISSN":["2352-1872"],"issn-type":[{"value":"2352-1872","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lessons learned from the real-world diagnosis and management of hereditary hypophosphatemic rickets","name":"articletitle","label":"Article Title"},{"value":"Bone Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bonr.2024.101753","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101753"}}